Targeting castration-resistant prostate cancer with monoclonal antibodies and constructs

By Slovin Susan F  

Immunotherapy, Vol. 5, Iss. 12, 2013-12 ,pp. : 1347-1355

Future Medicine

Access to resources Recommend Favorite

The prognostic significance of loss of the androgen receptor and neuroendocrine differentiation in prostate biopsy specimens among castration-resistant prostate cancer patients

By Komiya  

Molecular and Clinical Oncology, Vol. 1, Iss. 2, 2013-01 ,pp. : 257-262

Spandidos Publications

Access to resources Recommend Favorite

Docetaxel-based therapy with and without antiangiogenic agents as first-line chemotherapy for castration-resistant prostate cancer: A meta-analysis of nine randomized controlled trials

By              

Molecular and Clinical Oncology, Vol. 2, Iss. 6, 2014-01 ,pp. : 1182-1188

Spandidos Publications

Access to resources Recommend Favorite

Immunotherapy as part of combinations for the treatment of cancer

By Mitchell M.S.  

International Immunopharmacology, Vol. 3, Iss. 8, 2003-08 ,pp. : 1051-1059

Elsevier

Access to resources Recommend Favorite

Renal transplantation and prostate cancer: guidelines for screening and treatment

By Whang M.   Geffner S.   Khachikian Z.   Kumar A.   Bonomini L.   Mulgaonkar S.  

Transplantation Proceedings, Vol. 34, Iss. 8, 2002-12 ,pp. : 3196-3199

Elsevier

Access to resources Recommend Favorite